Nasal spray weight loss drug enters human testing
NCT ID NCT07465965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new nasal spray form of semaglutide (a weight-loss drug) in 60 overweight or obese adults. The main goal is to check safety and how the body processes the drug, not to prove weight loss yet. Participants receive a single dose and are monitored closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Frontage Clinical Services, Inc.
RECRUITINGSecaucus, New Jersey, 07094, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?